Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination

ABSTRACT

Summary of recent changes (last updated September 2, 2022) Updated guidance for observation periods following COVID-19 vaccination Key Points Anaphylaxis, an acute and potentially life-threatening allergic reaction, has been reported rarely following COVID-19 vaccination. Under the Emergency Use Authorizations for COVID-19 vaccines, appropriate medical treatment for severe allergic reactions must be immediately available at any site administering the vaccine in the event that an acute anaphylactic reaction occurs following administration of a COVID-19 vaccine. These interim considerations provide information on preparing for the initial assessment and potential management of anaphylaxis following COVID-19 vaccination. On This Page Personnel, medications, and supplies for assessing and managing anaphylaxis Post-vaccination observation periods Early recognition of anaphylaxis Management of anaphylaxis at a COVID-19 vaccination location Considerations for anaphylaxis management in special populations Patient counseling Reporting anaphylaxis Additional resources References Appendix Previous Updates Overview Anaphylaxis, an acute and potentially life-threatening allergic reaction, has been reported rarely following COVID-19 vaccination. These interim considerations provide recommendations on assessment and potential management of anaphylaxis following COVID-19 vaccination. Detailed information on CDC recommendations for vaccination, including contraindications and precautions to vaccination, can be found in the Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. Patients should be screened prior to receipt of each vaccine dose, and those with a contraindication should not be vaccinated. A COVID-19 prevaccination questionnaire [6 pages] is available to assist with screening.